MRI-derived LACI improves sudden cardiac death risk prediction in hypertrophic cardiomyopathy beyond ESC models. Find out ...

Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings.

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - ...

GE HealthCare doses first patient in Phase 2/3 LUMINA trial for mangaciclanol, a manganese MRI contrast agent with FDA Fast ...

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best NASDAQ stocks with the highest upside potential.

GE HealthCare doses first patient in phase 2/3 LUMINA trial for manganese-based MRI contrast agent, mangaciclanol: Chalfont St Giles,?UK Saturday, April 25, 2026, 12:00 Hrs [IST] ...

On April 18, Andrew Slimmon, Managing Director & Senior Portfolio Manager at Morgan Stanley Investment Management, appeared ...

These results underscore that fenebrutinib has potential as a high-efficacy oral treatment for RMS. Its unique mode of action may offer a differentiated profile by targeting dual drivers of MS within ...

Energy Fuels Inc. (NYSEAMERICAN:UUUU) is one of the best rare earth stocks to buy right now. On April 18, Energy Fuels Inc.

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS: Basel Thursday, April 23, 2026, 10:00 Hrs [IST] Roche ann ...

In seven patients, there were no signs of toxicity with proton-beam radioablation, clearing the way for future studies.

Investigational deramiocel is back under FDA review again ...